Kyverna Therapeutics to Present New Data of KYV-101 in Lupus at European Congress of Rheumatology

Preclinical data demonstrated strong activity of KYV-101 derived from patients with lupus, a key prerequisite for positive outcomes Research conducted in partnership with University of Erlangen Data to be presented in poster session and industry-sponsored symposium about CAR T-cell…